{"article_title": "Poltroons and pick-up lines: What's buzzing at #JPM15", "article_keywords": ["week", "biotech", "true", "whats", "heres", "maybe", "jpmpickuplines", "lines", "times", "company", "pickup", "usually", "buzzing", "jpm15", "poltroons"], "article_url": "http://medcitynews.com/2015/01/poltroons-pick-lines-whats-buzzing-jpm15/", "article_text": "Happy JP MorganWeek!\n\nPresenting companies have been bottling up the best news they can muster, to announce with aplomb this week at the premier biotech investing event in the country.\n\nIt\u2019s already begun: Shire just acquired NPS Pharmaceuticals for a whopping $5.2 billion \u2013 not a shocking acquisition, but a large and well-timed one. And XConomy just dished a roundup of spanking-new life sci deals \u2013 the \u201cPre-JP Morgan Preening Edition.\u201d More shall invariably come. But beyond the big deals, here\u2019s some of the buzz surrounding next week\u2019s madness:\n\nAdvertisement\n\nVenture capitalist Bruce Booth\u2018s pithiness is on full display in this hilarious piece penned for Forbes that outlines the expected chatter, as pharma cronies rub elbows and get tanked:\n\n\u201cWe\u2019ve established definitive clinical proof of concept in You\u2019ve-Never-Heard-Of-This-Orphan-Disease\u201d and are heading towards registration trials. With 7000 orphan diseases, this statement just may be true no matter how many times you hear it.\n\nand are heading towards registration trials. With 7000 orphan diseases, this statement just may be true no matter how many times you hear it. \u201cWe\u2019re going to be the Agios-of-X\u2026\u201d Conveyed during private biotech pitches as a \u201ccomparable\u201d future trajectory, like the Uber-of-X theme in tech. Maybe true, maybe not \u2013 but $AGIO is a pretty special 1-in-500 type of company.\n\nConveyed during private biotech pitches as a \u201ccomparable\u201d future trajectory, like the Uber-of-X theme in tech. Maybe true, maybe not \u2013 but $AGIO is a pretty special 1-in-500 type of company. \u201cIf only we could have done that tax inversion deal\u2026\u201d Maybe we won\u2019t hear this one, but I\u2019m sure there are a lot of CFOs and buyside investors daydreaming about it\n\nAdam Feuerstein wrote a couple useful tip sheets for what some of the bigger players have in store. Here\u2019s part one, and here\u2019s part two. Excerpt:\n\nNovartis (NVS)\n\nMon. Jan. 12 at 12 PM ET\n\nWebcast: Presentation only CAR-T. CAR-T. CAR-T. Is there really anything else?\n\nFeuerstein also pointed out how few of the presenting companies plan to webcast their Q&As \u2013 \u201cproving once again that some antiquated barriers to investor transparency remain stubbornly difficult to tear down.\u201d Forbes\u2018 Matthew Herper tweeted out Feuerstein\u2019s story:\n\nCEOs not broadcasting their #JPM15 breakouts are poltroons. via @adamfeuerstein http://t.co/jPXQgEcQrU \u2014 Matthew Herper (@matthewherper) January 7, 2015\n\nNice use of the word \u201cpoltroon.\u201d Means \u201cutter coward.\u201d CNBC put together an analysis of how the market overall performs surrounding JPM week \u2013 and when\u2019s best to invest in life science stocks. Here\u2019s a bit of what was said:\n\nThe S&P 500 usually rises during the week of the conference; it\u2019s up 77 percent of the time, with an average return of 0.32 percent over five days. But both the SPDR Health Care ETF and the iShares Nasdaq Biotech ETF typically outperform the S&P that week. Health care has returned an average of 1.56 percent, while biotech has increased an average 2.1 percent.\n\n\n\nIf you sell the first day of the conference, history would suggest you\u2019d miss out on the broader gains. Health care is usually up 0.76 percent the first day, while biotech usually rises 0.36 percent.\n\nRon Leuty over at the San Francisco Business Times posted a field guide to #JPM15, which \u2013 along with notes on how to find the closest massage parlor \u2013 points out:\n\nSome really interesting presenting companies, like Theranos Inc., the Palo Alto company that is the buzz of the consumer diagnostics world. Or former Genentech Inc. CEO Art Levinson\u2019s South San Francisco aging research company, Calico. Or Shockwave Medical, a Fremont company that this month won European regulatory approval for a balloon catheter to treat peripheral artery disease with powerful mechanical pulses.\n\nOh! And best thing ever: #JPMpickuplines. Some highlights:\n\nHey do you have an inhaler? Cause you got that ass ma! #jpmpickuplines \u2014 Thug Biotech Analyst (@Thug_BioAnalyst) January 17, 2014\n\nYour asset is hotter than a cancer immunotherapeutic Phase 3 candidate #jpmpickuplines \u2014 Jennifer Chang (@jenchang1) January 9, 2015\n\n\u201cTired of small molecules?\u201d #jpmpickuplines #JPM15 \u2014 erikclausen (@EClausen) January 7, 2015\n\nAw. Nerds are funny.", "article_metadata": {"description": "Happy JP MorganWeek! Presenting companies have been bottling\u00a0up the best news they can muster, to\u00a0announce with aplomb this week at\u00a0the premier biotech investing event in the country. It\u2019s already begun:\u00a0Shire just acquired NPS Pharmaceuticals for a whopping $5.2 billion \u2013 not a shocking acquisition, but a large and well-timed one. And XConomy just dished a roundup of spanking-new\u00a0life sci deals \u2013 the \u201cPre-JP Morgan Preening Edition.\u201d More shall invariably\u00a0come.\u00a0But beyond the big deals, here\u2019s some of the buzz surrounding next week\u2019s madness: Venture capitalist Bruce Booth\u2018s pithiness is on full display in this hilarious piece penned for Forbes\u00a0that outlines the expected chatter, as pharma cronies rub elbows and get tanked: \u00a0\u201cWe\u2019ve established definitive clinical proof of concept in You\u2019ve-Never-Heard-Of-This-Orphan-Disease\u201d\u00a0and are heading towards registration trials.\u00a0 With 7000 orphan diseases, this statement just may be true no matter how many times you hear it. \u201cWe\u2019re going to be the Agios-of-X\u2026\u201d\u00a0Conveyed during private biotech pitches as a \u201ccomparable\u201d future trajectory, like the Uber-of-X theme in tech.\u00a0 Maybe true, maybe not \u2013 but $AGIO is a pretty special 1-in-500 type of company. \u201cIf only we could have done\u00a0that tax inversion deal\u2026\u201d\u00a0\u00a0Maybe we won\u2019t hear this one, but I\u2019m sure there are a lot of CFOs and buyside investors daydreaming about it Adam Feuerstein wrote\u00a0a couple useful\u00a0tip sheets\u00a0for what some of the bigger players have in store. Here\u2019s part one, and here\u2019s part two. Excerpt: Novartis (NVS) Mon. Jan. 12 at 12 PM ET Webcast:\u00a0Presentation only CAR-T. CAR-T. CAR-T. Is there really anything else? Feuerstein also pointed out how few of the presenting companies plan to webcast their Q&As \u2013 \u201cproving once again that some antiquated barriers to investor transparency remain stubbornly difficult to tear down.\u201d Forbes\u2018 Matthew Herper tweeted out Feuerstein\u2019s story: CEOs not broadcasting their #JPM15 breakouts are poltroons. via @adamfeuerstein http://t.co/jPXQgEcQrU \u2014 Matthew Herper (@matthewherper) January 7, 2015 Nice\u00a0use of the word \u201cpoltroon.\u201d Means \u201cutter coward.\u201d CNBC put together an analysis of how the market overall performs surrounding JPM week \u2013 and when\u2019s best to invest in life science stocks. Here\u2019s a bit of what was said: The S&P 500 usually rises during the week of the conference; it\u2019s up 77 percent of the time, with an average return of 0.32 percent over five days. But both the SPDR Health Care ETF and the iShares Nasdaq Biotech ETF typically outperform the S&P that week. Health care has returned an average of 1.56 percent, while biotech has increased an average 2.1 percent. If you sell the first day of the conference, history would suggest you\u2019d miss out on the broader gains. Health care is usually up 0.76 percent the first day, while biotech usually rises 0.36 percent. Ron Leuty over at the San Francisco Business Times posted a field guide to #JPM15, which \u2013 along with notes on how to find the closest massage parlor \u2013 points out: Some really interesting presenting companies, like Theranos Inc., the Palo Alto company that is the buzz of the consumer diagnostics world. Or former Genentech Inc. CEO Art Levinson\u2019s South San Francisco aging research company, Calico. Or Shockwave Medical, a Fremont company that this month won European regulatory approval for a balloon catheter to treat peripheral artery disease with powerful mechanical pulses. Oh! And best thing ever:\u00a0#JPMpickuplines. Some highlights: Hey do you have an inhaler? Cause you got that ass ma! #jpmpickuplines \u2014 Thug Biotech Analyst (@Thug_BioAnalyst) January 17, 2014 Your asset is hotter than a cancer immunotherapeutic Phase 3 candidate #jpmpickuplines \u2014 Jennifer Chang (@jenchang1) January 9, 2015 \u201cTired of small molecules?\u201d #jpmpickuplines #JPM15 \u2014 erikclausen (@EClausen) January 7, 2015 Aw. Nerds are funny.", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "Happy JP MorganWeek! Presenting companies have been bottling\u00a0up the best news they can muster, to\u00a0announce with aplomb this week at\u00a0the premier biotech investing event in the country. It\u2019s already begun:\u00a0Shire just acquired NPS Pharmaceuticals for a whopping $5.2 billion \u2013 not a shocking acquisition, but a large and well-timed one. And XConomy just dished a roundup of spanking-new\u00a0life sci deals \u2013 the \u201cPre-JP Morgan Preening Edition.\u201d More shall invariably\u00a0come.\u00a0But beyond the big deals, here\u2019s some of the buzz surrounding next week\u2019s madness: Venture capitalist Bruce Booth\u2018s pithiness is on full display in this hilarious piece penned for Forbes\u00a0that outlines the expected chatter, as pharma cronies rub elbows and get tanked: \u00a0\u201cWe\u2019ve established definitive clinical proof of concept in You\u2019ve-Never-Heard-Of-This-Orphan-Disease\u201d\u00a0and are heading towards registration trials.\u00a0 With 7000 orphan diseases, this statement just may be true no matter how many times you hear it. \u201cWe\u2019re going to be the Agios-of-X\u2026\u201d\u00a0Conveyed during private biotech pitches as a \u201ccomparable\u201d future trajectory, like the Uber-of-X theme in tech.\u00a0 Maybe true, maybe not \u2013 but $AGIO is a pretty special 1-in-500 type of company. \u201cIf only we could have done\u00a0that tax inversion deal\u2026\u201d\u00a0\u00a0Maybe we won\u2019t hear this one, but I\u2019m sure there are a lot of CFOs and buyside investors daydreaming about it Adam Feuerstein wrote\u00a0a couple useful\u00a0tip sheets\u00a0for what some of the bigger players have in store. Here\u2019s part one, and here\u2019s part two. Excerpt: Novartis (NVS) Mon. Jan. 12 at 12 PM ET Webcast:\u00a0Presentation only CAR-T. CAR-T. CAR-T. Is there really anything else? Feuerstein also pointed out how few of the presenting companies plan to webcast their Q&As \u2013 \u201cproving once again that some antiquated barriers to investor transparency remain stubbornly difficult to tear down.\u201d Forbes\u2018 Matthew Herper tweeted out Feuerstein\u2019s story: CEOs not broadcasting their #JPM15 breakouts are poltroons. via @adamfeuerstein http://t.co/jPXQgEcQrU \u2014 Matthew Herper (@matthewherper) January 7, 2015 Nice\u00a0use of the word \u201cpoltroon.\u201d Means \u201cutter coward.\u201d CNBC put together an analysis of how the market overall performs surrounding JPM week \u2013 and when\u2019s best to invest in life science stocks. Here\u2019s a bit of what was said: The S&P 500 usually rises during the week of the conference; it\u2019s up 77 percent of the time, with an average return of 0.32 percent over five days. But both the SPDR Health Care ETF and the iShares Nasdaq Biotech ETF typically outperform the S&P that week. Health care has returned an average of 1.56 percent, while biotech has increased an average 2.1 percent. If you sell the first day of the conference, history would suggest you\u2019d miss out on the broader gains. Health care is usually up 0.76 percent the first day, while biotech usually rises 0.36 percent. Ron Leuty over at the San Francisco Business Times posted a field guide to #JPM15, which \u2013 along with notes on how to find the closest massage parlor \u2013 points out: Some really interesting presenting companies, like Theranos Inc., the Palo Alto company that is the buzz of the consumer diagnostics world. Or former Genentech Inc. CEO Art Levinson\u2019s South San Francisco aging research company, Calico. Or Shockwave Medical, a Fremont company that this month won European regulatory approval for a balloon catheter to treat peripheral artery disease with powerful mechanical pulses. Oh! And best thing ever:\u00a0#JPMpickuplines. Some highlights: Hey do you have an inhaler? Cause you got that ass ma! #jpmpickuplines \u2014 Thug Biotech Analyst (@Thug_BioAnalyst) January 17, 2014 Your asset is hotter than a cancer immunotherapeutic Phase 3 candidate #jpmpickuplines \u2014 Jennifer Chang (@jenchang1) January 9, 2015 \u201cTired of small molecules?\u201d #jpmpickuplines #JPM15 \u2014 erikclausen (@EClausen) January 7, 2015 Aw. Nerds are funny.", "title": "Poltroons and pick-up lines: What\u2019s buzzing at #JPM15", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/5146901365_dd08f61324_o.jpg", "updated_time": "2016-01-11T09:53:47-04:00", "url": "http://medcitynews.com/2015/01/poltroons-pick-lines-whats-buzzing-jpm15/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/5146901365_dd08f61324_o.jpg", "creator": "@meghanakeshavan", "description": "Happy JP MorganWeek! Presenting companies have been bottling\u00a0up the best news they can muster, to\u00a0announce with aplomb this week at\u00a0the premier biotech investing event in the country. It\u2019s already begun:\u00a0Shire just acquired NPS Pharmaceuticals for a whopping $5.2 billion \u2013 not a shocking acquisition, but a large and well-timed one. And XConomy just dished a roundup of spanking-new\u00a0life sci deals \u2013 the \u201cPre-JP Morgan Preening Edition.\u201d More shall invariably\u00a0come.\u00a0But beyond the big deals, here\u2019s some of the buzz surrounding next week\u2019s madness: Venture capitalist Bruce Booth\u2018s pithiness is on full display in this hilarious piece penned for Forbes\u00a0that outlines the expected chatter, as pharma cronies rub elbows and get tanked: \u00a0\u201cWe\u2019ve established definitive clinical proof of concept in You\u2019ve-Never-Heard-Of-This-Orphan-Disease\u201d\u00a0and are heading towards registration trials.\u00a0 With 7000 orphan diseases, this statement just may be true no matter how many times you hear it. \u201cWe\u2019re going to be the Agios-of-X\u2026\u201d\u00a0Conveyed during private biotech pitches as a \u201ccomparable\u201d future trajectory, like the Uber-of-X theme in tech.\u00a0 Maybe true, maybe not \u2013 but $AGIO is a pretty special 1-in-500 type of company. \u201cIf only we could have done\u00a0that tax inversion deal\u2026\u201d\u00a0\u00a0Maybe we won\u2019t hear this one, but I\u2019m sure there are a lot of CFOs and buyside investors daydreaming about it Adam Feuerstein wrote\u00a0a couple useful\u00a0tip sheets\u00a0for what some of the bigger players have in store. Here\u2019s part one, and here\u2019s part two. Excerpt: Novartis (NVS) Mon. Jan. 12 at 12 PM ET Webcast:\u00a0Presentation only CAR-T. CAR-T. CAR-T. Is there really anything else? Feuerstein also pointed out how few of the presenting companies plan to webcast their Q&As \u2013 \u201cproving once again that some antiquated barriers to investor transparency remain stubbornly difficult to tear down.\u201d Forbes\u2018 Matthew Herper tweeted out Feuerstein\u2019s story: CEOs not broadcasting their #JPM15 breakouts are poltroons. via @adamfeuerstein http://t.co/jPXQgEcQrU \u2014 Matthew Herper (@matthewherper) January 7, 2015 Nice\u00a0use of the word \u201cpoltroon.\u201d Means \u201cutter coward.\u201d CNBC put together an analysis of how the market overall performs surrounding JPM week \u2013 and when\u2019s best to invest in life science stocks. Here\u2019s a bit of what was said: The S&P 500 usually rises during the week of the conference; it\u2019s up 77 percent of the time, with an average return of 0.32 percent over five days. But both the SPDR Health Care ETF and the iShares Nasdaq Biotech ETF typically outperform the S&P that week. Health care has returned an average of 1.56 percent, while biotech has increased an average 2.1 percent. If you sell the first day of the conference, history would suggest you\u2019d miss out on the broader gains. Health care is usually up 0.76 percent the first day, while biotech usually rises 0.36 percent. Ron Leuty over at the San Francisco Business Times posted a field guide to #JPM15, which \u2013 along with notes on how to find the closest massage parlor \u2013 points out: Some really interesting presenting companies, like Theranos Inc., the Palo Alto company that is the buzz of the consumer diagnostics world. Or former Genentech Inc. CEO Art Levinson\u2019s South San Francisco aging research company, Calico. Or Shockwave Medical, a Fremont company that this month won European regulatory approval for a balloon catheter to treat peripheral artery disease with powerful mechanical pulses. Oh! And best thing ever:\u00a0#JPMpickuplines. Some highlights: Hey do you have an inhaler? Cause you got that ass ma! #jpmpickuplines \u2014 Thug Biotech Analyst (@Thug_BioAnalyst) January 17, 2014 Your asset is hotter than a cancer immunotherapeutic Phase 3 candidate #jpmpickuplines \u2014 Jennifer Chang (@jenchang1) January 9, 2015 \u201cTired of small molecules?\u201d #jpmpickuplines #JPM15 \u2014 erikclausen (@EClausen) January 7, 2015 Aw. Nerds are funny.", "card": "summary", "title": "Poltroons and pick-up lines: What's buzzing at #JPM15 - MedCity News"}, "fb": {"app_id": 148725768475669}, "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,events, J.P. Morgan Healthcare Conference, OB, San Francisco, , MedCity News", "article": {"section": "Health IT", "tag": "San Francisco", "published_time": "2015-01-11T13:41:56-04:00", "modified_time": "2016-01-11T09:53:47-04:00"}, "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "_id": "\"57477af46914bd0286fdcafc\"", "article_summary": "Maybe true, maybe not \u2013 but $AGIO is a pretty special 1-in-500 type of company.\nHealth care is usually up 0.76 percent the first day, while biotech usually rises 0.36 percent.\n#jpmpickuplines \u2014 Thug Biotech Analyst (@Thug_BioAnalyst) January 17, 2014Your asset is hotter than a cancer immunotherapeutic Phase 3 candidate #jpmpickuplines \u2014 Jennifer Chang (@jenchang1) January 9, 2015\u201cTired of small molecules?\u201d #jpmpickuplines #JPM15 \u2014 erikclausen (@EClausen) January 7, 2015Aw.\nAnd XConomy just dished a roundup of spanking-new life sci deals \u2013 the \u201cPre-JP Morgan Preening Edition.\u201d More shall invariably come.\nWith 7000 orphan diseases, this statement just may be true no matter how many times you hear it."}